InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of InspireMD (NYSE:NSPR) in a research report released on Sunday. The brokerage issued a sell rating on the stock.

InspireMD Stock Performance

NYSE NSPR opened at $2.72 on Friday. InspireMD has a one year low of $1.81 and a one year high of $3.85. The company has a 50-day simple moving average of $2.76 and a 200-day simple moving average of $2.51. The firm has a market capitalization of $67.81 million, a PE ratio of -3.58 and a beta of 0.90.

InspireMD (NYSE:NSPR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The company had revenue of $1.74 million during the quarter, compared to analyst estimates of $1.74 million. InspireMD had a negative net margin of 388.67% and a negative return on equity of 62.02%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share. Equities analysts forecast that InspireMD will post -0.82 earnings per share for the current year.

Institutional Trading of InspireMD

A hedge fund recently raised its stake in InspireMD stock. Rosalind Advisors Inc. grew its position in InspireMD, Inc. (NYSE:NSPR) by 266.4% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,513,641 shares of the company’s stock after purchasing an additional 1,827,579 shares during the period. InspireMD makes up approximately 4.6% of Rosalind Advisors Inc.’s holdings, making the stock its 8th biggest position. Rosalind Advisors Inc. owned 10.08% of InspireMD worth $6,272,000 at the end of the most recent quarter. 44.78% of the stock is currently owned by institutional investors and hedge funds.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.